维亚生物科技控股集团
VIVA BIOTECH HOLDINGS
Stock Code：1873.HK

NEWSLETTER Issue 11
May – Jul 2022

VIVA Company News

Viva Biotech Successfully Held The 3rd Annual Partnership Summit

June 16th-20th, 2022, Viva Biotech 2022 Partnership Summit was successfully held. More than 260 attendees, including representatives from global investment institutions, R&D heads from pharmaceutical companies, and business development leaders, joined the Summit and conducted more than 300 one-on-one online meetings with the founders of nearly 70 VBI incubated portfolio companies through the Partnering Platform.

As one of the largest annual events held by Viva, the Partnership Summit is committed to gathering the leading forces from the scientific research community, biopharma industry, capital groups and more to assist biotech start-ups in achieving development success and commercialization.

VIVA Linkedin

Research & Development Progress

CDE Accepted the IND Application of Genhouse's ERK1/2 Inhibitor GH55

On July 12, 2022, Genhouse Bio announced that the Center for Drug Evaluation (CDE) has accepted the IND application for the new Class I drug, GH55 recently. At the same time, Genhouse Bio is actively preparing for the IND filing of this program in the U.S. The clinical trial application of GH55 further improves the strategic layout of Genhouse Bio's 1.0 pipeline in the RAS/MAPK signaling pathway.

Research & Development Progress

VVN539, an Innovative Dual-target Glaucoma Drug Independently Developed by VivaVision, Completed the Enrollment of the First Patient in Phase 2 Clinical Trials in the United States

On July 8, 2022, VivaVision announced that its self-developed dual-target drug VVN539 has completed the first patient enrollment of the Phase 2 clinical study for patients with open-angle glaucoma in Rochester Ophthalmological Group, New York, USA. This sets a new milestone of the first independent innovation drug for glaucoma in China entering a stage for rapid advancement.

Anji Pharma Provides Updates on Two Lead Programs

Recently, Anji Pharma shared updates on two lead programs, ANJ908 and ANJ900, at Digestive Disease Week (DDW) and the 82nd Scientific Sessions of the American Diabetes Association (ADA), respectively. Anji Pharma has completed patient enrollment in the Phase 2 study of ANJ908 (pradigastat) in chronic idiopathic constipation. Meanwhile, Anji Pharma is enrolling type 2 diabetes (T2D) patients with normal, mild, and moderate chronic kidney disease (CKD stages 1-3B) in a global Phase 3 study of ANJ900 (metformin delayed-release). It's on track for Q4 2022 expansion of ANJ900 global program into T2D with CKD3B/4 in the U.S., China, and the rest of the world.

Anji Pharma Completes Patient Enrollment in Phase 2 Study of Pradigastat in Functional Constipation

On May 20, 2022, Anji Pharma announced it has completed enrollment in its Phase 2 proof of concept study of pradigastat (ANJ908), a diacylglycerol acyltransferase 1 (DGAT1) inhibitor, in patients with functional constipation. Anji Pharma plans to report topline data from this study in the second half of 2022 and launch the Phase 3 clinical trial worldwide in 2023.

QureBio to Showcase its Q-1802 Clinical Advances at 2022 ASCO Annual Meetings

QureBio announced that its Q-1802 clinical program was selected for presentation at American Society of Clinical Oncology (ASCO) Annual Meetings. The presentation will showcase the preliminary results of a first-in-human Phase 1a/1b, multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity Q-1802, a Claudin18.2/PD-L1 bi-specific therapeutic in patients with relapsed or refractory solid tumors after standard therapies. The key data from the mono-therapy of Q-1802 in both dose-escalation and dose-expansion studies demonstrate excellent safety, tolerability, and preliminary anti-tumor activities of Q-1802 at the dose up to 10 mpk. The abstract for the study is found in 2022-ASCO-Annual-Meeting Abstracts (#2568).

Research & Development Progress

VivaVision Announces that VVN539 Has Been Formally Submitted for U.S. Phase 2 Clinical Trial Application

On May 5, 2022, VivaVision announced that it has submitted a Phase 2 clinical trial application for the new drug VVN539 for the treatment of open-angle glaucoma to the FDA and will start the clinical study in June 2022. VVN539 is the next clinical stage project of VivaVision after VVN001, which is expected to become a competitive ophthalmic drug globally.

Business Progress

AIxplorerBIO and the Institute of Immunology at Tsinghua University Reached a Strategic Collaboration Agreement to Explore and Promote the R&D of New Drugs in the Field of Autoimmunity

Recently, AIxplorerBIO reached a strategic collaboration agreement with the Institute of Immunology at Tsinghua University in the field of autoimmunity on the pathogenesis of selected diseases, the selection and validation of relevant targets, and other topics of mutual interests. This strategic collaboration, combined with the AIxplorerBio team's rich experience in drug R&D, coupled with the company's comprehensive AI drug discovery platform AIxMol, will position AIxplorerBio at the forefront in the AI drug discovery race to bring better treatment options to patients with autoimmune diseases. The two sides held their first pipeline strategy meeting in Beijing on July 19.

Domain Therapeutics receives a single digit multimillion development milestone payment from Merck for M1069 clinical development in immuno-oncology

On June 28, 2022, Domain Therapeutics announced that it obtained a single digit multimillion milestone payment from Merck. A2a/A2b antagonist candidate, M1069, jointly discovered by Domain Therapeutics and Merck entered into a first-in-human study. This productive and successful partnership, based on Domain's expertise in GPCR medicinal chemistry, pharmacology and drug discovery, led to the identification of the drug candidate M1069 to be included in the oncology pipeline of Merck. This drug candidate is the first out of Domain's pipeline to reach clinical development stage in immuno-oncology.

Business Progress

Amberstone Biosciences Announces Formation of Scientific Advisory Board

Recently, Amberstone Biosciences announced the formation of a scientific advisory board which is comprised of industry leaders in the top fields of drug delivery, oncology, immunology, and pharmaceutical sciences. The advisory board will work closely with Amberstone to jointly advance the company's therapeutic programs based on its Tumor Microenvironment Activated Therapeutics (T-MATE) platform.

VivaVision and Acemab Reached a Strategic Collaboration Agreement, To Jointly Develop Antibody Drugs For Fundus Diseases

On May 18, 2022, VivaVision announced a collaboration with Acemab to co-develop bispecific antibody drugs for fundus diseases. The collaboration integrates the strengths of Acemab's bispecific antibody discovery platform to enable the development of VivaVision's sustained-release molecules for the fundus disease which in the meantime provides a good foundation for the subsequent process development.

AIxplorerBio Entered a Broad Collaboration with Baidu's PaddleHelix to Expedite the Construction of Its AI Small Molecule Drug R&D Platform

On May 18, 2022, AIxplorerBio, a Viva BioInnovator portfolio company, announced a broad collaboration with PaddleHelix. The two parties will leverage their strengths and collaborate in the fields of de novo molecular design and druggability evaluation to accelerate new AI-powered drug research and development platform. The collaboration between AIxplorerBio and PaddleHelix, which started in 2021, is focused on the field of drug evaluation of ADMET（absorption, tissue distribution, metabolism, excretion and toxicity）compounds and virtual screening of small molecular drugs, with some milestones achieved.

Investment Progress

Domain Therapeutics Completed US$42 Million Series A Financing

On May 10, 2022, Domain Therapeutics announced the closing of a US$42 million (€39 million) series A financing round co-led by Panacea Venture, CTI Life Sciences and 3B Future Health Fund, and joined by adMare BioInnovations, Schroders Capital, Omnes, Turenne Capital, Theodorus, Viva BioInnovator and existing investor Seventure Partners.

About Viva Biotech

Listing Date
2019.05.09
Price (2022.08.11)
HKD 2.14
52 WK Range
HKD 2.00 – 7.59
Market Cap (2022.08.11)
HKD 4.14B

Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage Structure-Based Drug R&D to commercial drug delivery to global biopharmaceutical innovators. We offer leading early-stage to late-phase drug discovery expertise by integrating our dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, ASMS, SPR, HDX, CADD, etc.. Our business covers all aspects of therapeutic strategies and drug modalities including small molecules and biologics across the pharma and biotech spectrum. Through our subsidiary Langhua Pharma, we offer our worldwide pharmaceutical and biotech partners One-Stop integrated CMC (Chemical, Manufacturing, and Control) service from preclinical to commercial manufacturing. In addition, Viva has embedded an equity for service (EFS) model to high potential startups to address unmet medical needs.

As of December 31, 2021, Viva Biotech has provided drug R&D and production services to 1,820 biotech and pharmaceutical clients around the world. We have invested and incubated 87 biotech start-ups in total. In the future, the Company will continue to strengthen its technical barriers, improve R&D and production level, and the service capacity, so as to provide high-quality and diversified services for more drug discovery start-ups, as well as the medium and large pharmaceutical enterprises around the world. We hope to benefit more patients through Viva's platform.

Investor & Media Enquiries

Viva Biotech Holdings website: www.vivabiotech.com
For further information, please contact: Tel: 852-3150 6788
Email: ir@vivabiotech.com; VivaBiotech.hk@pordahavas.com